Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Jul 10;6(19):17354-65.
doi: 10.18632/oncotarget.4008.

Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies

Liang Xia  1 , Bin Wu  1 , Zhiquan Fu  2 , Fang Feng  1 , Enqi Qiao  1 , Qinglin Li  1 , Caixing Sun  1 , Minghua Ge  1
Affiliations
Meta-Analysis

Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies

Liang Xia et al. Oncotarget. .

Abstract

Background: IDH (Isocitrate dehydrogenase) mutations occur frequently in gliomas, but their prognostic impact has not been fully assessed. We performed a meta-analysis of the association between IDH mutations and survival in gliomas.

Methods: Pubmed and EMBASE databases were searched for studies reporting IDH mutations (IHD1/2 and IDH1) and survival in gliomas. The primary outcome was overall survival (OS); the secondary outcome was progression-free survival (PFS). Hazard ratios (HR) with 95% confidence interval (CI) were determined using the Mantel-Haenszel random-effect modeling. Funnel plot and Egger's test were conducted to examine the risk of publication bias.

Results: Fifty-five studies (9487 patients) were included in the analysis. Fifty-four and twenty-seven studies investigated the association between IDH1/2 mutations and OS/PFS respectively in patients with glioma. The results showed that patients possessing an IDH1/2 mutation had significant advantages in OS (HR = 0.39, 95%CI: 0.34-0.45; P < 0.001) and PFS (HR = 0.42, 95% CI: 0.35-0.51; P < 0.001). Subgroup analysis showed a consistent result with pooled analysis, and patients with glioma of WHO grade III or II-III had better outcomes.

Conclusions: These findings provide further indication that patients with glioma harboring IDH mutations have improved OS and PFS, especially for patients with WHO grade III and grade II-III.

Keywords: IDH mutations; glioma; prognosis.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

All authors declare that they have no conflict of interests.

Figures

Figure 1
Figure 1. Flowchart of the included studies
Figure 2
Figure 2. Forest plot of HR and 95%CI of the association between IDH1/2 mutations and OS of gliomas
Figure 3
Figure 3. Forest plot of HR and 95%CI of the association between IDH1/2 mutations and PFS of gliomas
Figure 4
Figure 4. Egger's funnel plot for the publication bias test of the IDH1/2 mutations and OS A. or PFS B. of human gliomas
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stupp R, Tonn JC, Brada M, Pentheroudakis G. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21:v190–193. - PubMed
    1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica. 2005;109:93–108. - PubMed
    1. Feiden S, Feiden W. [WHO classification of tumours of the CNS: revised edition of 2007 with critical comments on the typing und grading of common-type diffuse gliomas] Der Pathologe. 2008;29:411–421. - PubMed
    1. Fuentes-Raspall R, Vilardell L, Perez-Bueno F, Joly C, Garcia-Gil M, Garcia-Velasco A, et al. Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994–2005. Journal of neuro-oncology. 2011;101:117–123. - PubMed
    1. Huse JT, Aldape KD. The evolving role of molecular markers in the diagnosis and management of diffuse glioma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20:5601–5611. - PubMed

Publication types